Cuprizone neurotoxicity, copper deficiency and neurodegeneration

NeuroToxicology

Volumn 31, Issue 5, 2010, Pages 509-517

  Benetti, Federico ^a   Ventura, Marcello ^a   Salmini, Benedetta ^a   Ceola, Stefano ^a   Carbonera, Donatella ^a   Mammi, Stefano ^a   Zitolo, Andrea ^b   D'Angelo, Paola ^b   Urso, Emanuela ^c   Maffia, Michele ^c   Salvato, Benedetto ^a   Spisni, Enzo ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ceruloplasmin activity; Copper deficiency; Cuprizone; Neurodegeneration

Indexed keywords

CERULOPLASMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; COPPER DEFICIENCY; DEGENERATIVE DISEASE; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NERVE CELL CULTURE; NERVE CELL MEMBRANE; NEUROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMALS; BRAIN; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CERULOPLASMIN; COPPER; CUPRIZONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; MASS SPECTROMETRY; MICE; MONOAMINE OXIDASE INHIBITORS; NERVE DEGENERATION; NEUROBLASTOMA; NEUROTOXICITY SYNDROMES; OXIDOREDUCTASES; PHYSICOCHEMICAL PROCESSES; SPECTROPHOTOMETRY, ATOMIC;

MUS;

EID: 77956227296     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.05.008     Document Type: Article

References (49)

1. Bakker D.A., Ludwig S.K. Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 1987, 78:125-137.
2. Barnard R.O., Best P.V., Erdohazi M. Neuropathology of Menkes' disease. Dev Med Child Neurol 1978, 20:586-597.
3. Bertini I., Rosato A. Menkes disease. Cell Mol Life Sci 2008, 65:89-91.
4. Binder M.D., Cate H.S., Prieto A.L., Kemper D., Butzkueven H., Gresle M.M., et al. Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. J Neurosci 2008, 28:5195-5206.
5. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci 2003, 26:207-214.
6. Carlton W.W. Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. Life Sci 1967, 6:11-19.
7. Chelly J., Tumer Z., Tonnesen T., Petterson A., Ishikawa-Brush Y., Tommerup N., et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993, 3:14-19.
8. Curzon G., Vallet L. The purification of human caeruloplasmin. Biochem J 1960, 74:279-287.
9. Geller T.J., Pan Y., Martin D.S. Early neuroradiologic evidence of degeneration in Menkes' disease. Pediatr Neurol 1997, 17:255-258.
10. Harvey L.J., McArdle H.J. Biomarkers of copper status: a brief update. Br J Nutr 2008, 99(Suppl. 3):S10-S13.
11. Healy J., Tipton K. Ceruloplasmin and what it might do. J Neural Transm 2007, 114:777-781.
12. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002, 22:439-458.
13. Hiremath M.M., Saito Y., Knapp G.W., Ting J.P., Suzuki K., Matsushima G.K. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 1998, 92:38-49.
14. Holmberg C.G. On the presence of a laccase-like enzyme in serum and its relation to the copper in serum. Acta Physiol Scand 1944, 8:227-229.
15. Holmberg C.G., Laurell C.B. Investigations in serum copper II, isolation of the copper-containing protein and a description of some of its properties. Acta Chem Scand 1948, 2:550-556.
16. Howell G.A., Welch M.G., Frederickson C.J. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 1984, 308:736-738.
17. Kaler S.G., Buist N.R., Holmes C.S., Goldstein D.S., Miller R.C., Gahl W.A. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol 1995, 38:921-928.
18. Kodama H., Murata Y., Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int 1999, 41:423-429.
19. Kondo A., Nakano T., Suzuki K. Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res 1987, 425:186-190.
20. Leventer R.J., Kornberg A.J., Phelan E.M., Kean M.J. Early magnetic resonance imaging findings in Menkes' disease. J Child Neurol 1997, 12:222-224.
21. Linder M.C. Biochemistry of copper 1991, Plenum Press, New York, pp. 1-13.
22. Lontie R. Copper proteins and copper enzymes 1984, CRC Press, Boca Raton, FL.
23. Madsen E., Gitlin J.D. Copper and iron disorders of the brain. Annu Rev Neurosci 2007, 30:317-337.
24. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001, 11:107-116.
25. Mercer J.F., Livingston J., Hall B., Paynter J.A., Begy C., Chandrasekharappa S., et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet 1993, 3:20-25.
26. Messori L., Casini A., Gabbiani C., Sorace L., Muniz-Miranda M., Zatta P. Unravelling the chemical nature of copper cuprizone. Dalton Trans 2007, 2112-2114.
27. Muniz-Miranda M., Pagliai M., Cardini G., Messori L., Bruni B., Casini A., et al. A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state. CrystEngComm 2008, 10:416-422.
28. Oder W., Grimm G., Kollegger H., Ferenci P., Schneider B., Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol 1991, 238:281-287.
29. Okeda R., Gei S., Chen I., Okaniwa M., Shinomiya M., Matsubara O. Menkes' kinky hair disease: morphological and immunohistochemical comparison of two autopsied patients. Acta Neuropathol 1991, 81:450-457.
30. Pasquini L.A., Calatayud C.A., Bertone Una A.L., Millet V., Pasquini J.M., Soto E.F. The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res 2007, 32:279-292.
31. Percival S.S., Harris E.D. Copper transport from ceruloplasmin: characterization of the cellular uptake mechanism. Am J Physiol 1990, 258:C140-C146.
32. Peterson R.E., Bollier M.E. Spectrophotometric determination of serum copper with Biscyclohexanoneoxalyldihydrazone. Anal Chem 1955, 27:1195-1197.
33. Raivich G., Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 2004, 46:261-281.
34. Rossi L., De Martino A., Marchese E., Piccirilli S., Rotilio G., Ciriolo M.R. Neurodegeneration in the animal model of Menkes' disease involves Bcl-2-linked apoptosis. Neuroscience 2001, 103:181-188.
35. Schlief M.L., Craig A.M., Gitlin J.D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 2005, 25:239-246.
36. Small C.I., Lyles G.A., Breen K.C. Inducible form of nitric oxide synthase expression in rat cortical neuronal cells in vitro. Neurobiol Dis 2004, 17:70-76.
37. Spisni E., Bartolini G., Orlandi M., Belletti B., Santi S., Tomasi V. Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells. Exp Cell Res 1995, 219:507-513.
38. Spisni E., Valerii M.C., Manerba M., Strillacci A., Polazzi E., Mattia T., et al. Effect of copper on extracellular levels of key pro-inflammatory molecules in hypothalamic GN11 and primary neurons. Neurotoxicology 2009, 30(4):605-612.
39. Stidworthy M.F., Genoud S., Suter U., Mantei N., Franklin R.J. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 2003, 13:329-339.
40. Strozyk D., Bush A.I. The role of metal ions in neurology. An introduction. Metal Ions Life Sci 2006, 1:1-7.
41. Suzuki K., Kikkawa Y. Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone). Am J Pathol 1969, 54:307-325.
42. Ungell A.L., Nylander S., Bergstrand S., Sjöberg A., Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998, 87:360-366.
43. Vassiliev V., Harris Z.L., Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005, 49:633-640.
44. Venturini G. Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem 1973, 21:1147-1151.
45. Vulpe C., Levinson B., Whitney S., Packman S., Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993, 3:7-13.
46. Watt N.T., Hooper N.M. The response of neurones and glial cells to elevated copper. Brain Res Bull 2001, 55:219-224.
47. Werner S.R., Saha J.K., Broderick C.L., Zhen E.Y., Higgs R.E., Duffin K.L., et al. Proteomic analysis of demyelinated and remyelinating brain tissue following dietary cuprizone administration. J Mol Neurosci 2010, (April). [Epub ahead of print].
48. Zatta P., Raso M., Zambenedetti P., Wittkowski W., Messori L., Piccioli F., et al. Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci 2005, 62:1502-1513.
49. Zucconi G.G., Cipriani S., Scattoni R., Balgkouranidou I., Hawkins D.P., Ragnarsdottir K.V. Copper deficiency elicits glial and neuronal response typical of neurodegenerative disorders. Neuropathol Appl Neurobiol 2007, 33:212-225.